HRP20220025T1 - Režim doziranja valbenazina za liječenje hiperkinetičkih poremećaja kretanja - Google Patents
Režim doziranja valbenazina za liječenje hiperkinetičkih poremećaja kretanja Download PDFInfo
- Publication number
- HRP20220025T1 HRP20220025T1 HRP20220025TT HRP20220025T HRP20220025T1 HR P20220025 T1 HRP20220025 T1 HR P20220025T1 HR P20220025T T HRP20220025T T HR P20220025TT HR P20220025 T HRP20220025 T HR P20220025T HR P20220025 T1 HRP20220025 T1 HR P20220025T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- use according
- daily dose
- treatment
- hyperkinetic movement
- Prior art date
Links
- 208000000269 Hyperkinesis Diseases 0.000 title claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 3
- GEJDGVNQKABXKG-CFKGEZKQSA-N [(2r,3r,11br)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl] (2s)-2-amino-3-methylbutanoate Chemical compound C1CN2C[C@@H](CC(C)C)[C@H](OC(=O)[C@@H](N)C(C)C)C[C@@H]2C2=C1C=C(OC)C(OC)=C2 GEJDGVNQKABXKG-CFKGEZKQSA-N 0.000 title 1
- 229950006411 valbenazine Drugs 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 4
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989240P | 2014-05-06 | 2014-05-06 | |
| PCT/US2015/029519 WO2015171802A1 (en) | 2014-05-06 | 2015-05-06 | Vmat2 inhibitors for the treatment of hyperkinetic movement disorders |
| EP15724438.5A EP3139925B1 (en) | 2014-05-06 | 2015-05-06 | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220025T1 true HRP20220025T1 (hr) | 2022-04-01 |
Family
ID=53264772
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240459TT HRP20240459T1 (hr) | 2014-05-06 | 2015-05-06 | Režim za doziranje valbenazina za liječenje hiperkinetskih poremećaja pokreta |
| HRP20220025TT HRP20220025T1 (hr) | 2014-05-06 | 2015-05-06 | Režim doziranja valbenazina za liječenje hiperkinetičkih poremećaja kretanja |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240459TT HRP20240459T1 (hr) | 2014-05-06 | 2015-05-06 | Režim za doziranje valbenazina za liječenje hiperkinetskih poremećaja pokreta |
Country Status (24)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7109360B2 (ja) | 2015-10-30 | 2022-07-29 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | バルベナジン塩およびその多形体 |
| CA3009169A1 (en) | 2015-12-23 | 2017-06-29 | Neurocrine Biosciences, Inc. | Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
| CN109153676B (zh) * | 2016-06-29 | 2021-08-10 | 苏州科睿思制药有限公司 | Nbi-98854的晶型及其制备方法和用途 |
| JP2020500875A (ja) * | 2016-12-02 | 2020-01-16 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
| US10703750B2 (en) | 2017-01-10 | 2020-07-07 | Sandoz Ag | Crystalline valbenazine free base |
| EA201991782A1 (ru) | 2017-01-27 | 2021-09-23 | Нейрокрин Байосайенсиз, Инк. | Способы введения некоторых vmat2-ингибиторов |
| CA3054238A1 (en) | 2017-02-27 | 2018-08-30 | Sandoz Ag | Crystalline forms of valbenazine salts |
| WO2018164996A1 (en) * | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| RU2022104034A (ru) * | 2017-04-01 | 2022-03-05 | Адептио Фармасьютикалз Лимитед | Фармацевтические композиции |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| RU2771164C2 (ru) * | 2017-04-01 | 2022-04-27 | Адептио Фармасьютикалз Лимитед | (+)-альфа-дигидротетрабеназин для использования при лечении двигательного расстройства |
| GB201705305D0 (en) * | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| US20190111035A1 (en) * | 2017-04-01 | 2019-04-18 | Adeptio Pharmaceuticals Limited | Pharmaceutical compositions |
| WO2018200605A1 (en) * | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| CN111372567B (zh) | 2017-09-21 | 2024-03-15 | 纽罗克里生物科学有限公司 | 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒 |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| WO2019074492A1 (en) * | 2017-10-10 | 2019-04-18 | Obrien Christopher F | METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS |
| US11306082B2 (en) * | 2017-11-08 | 2022-04-19 | Foresee Pharmaceuticals Co., Ltd. | Esters of dihydrotetrabenazine |
| WO2019129100A1 (zh) | 2017-12-26 | 2019-07-04 | 苏州科睿思制药有限公司 | 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途 |
| US12144899B2 (en) * | 2018-04-25 | 2024-11-19 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| MX2020013004A (es) | 2018-06-14 | 2021-02-17 | Neurocrine Biosciences Inc | Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. |
| IL320987A (en) | 2018-08-15 | 2025-07-01 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| WO2020070236A1 (en) | 2018-10-04 | 2020-04-09 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
| EP3965764A1 (en) * | 2019-05-09 | 2022-03-16 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| US10940141B1 (en) * | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2081929E (pt) * | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados |
| JP2010509336A (ja) * | 2006-11-09 | 2010-03-25 | ニューヨーク ユニバーシティ | サンドイッチ材料の製造方法、ガラス／セラミック／ガラス複合構造物、ガラス／セラミック／ガラス、医科あるいは歯科補綴、およびガラス／ジルコニア／ガラスサンドイッチ材料 |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| NO3061760T3 (cg-RX-API-DMAC7.html) | 2008-09-18 | 2018-04-07 | ||
| JP2013501810A (ja) * | 2009-08-12 | 2013-01-17 | ヴァリーント インターナショナル（バルバドス）エスアールエル | 医薬組成物 |
| CA2801061A1 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| NZ705372A (en) | 2012-09-18 | 2018-07-27 | Auspex Pharmaceuticals Inc | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| RU2021128797A (ru) * | 2014-02-07 | 2021-11-26 | Ньюрокрайн Байосайенсиз, Инк. | Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение |
-
2015
- 2015-05-06 JP JP2016566238A patent/JP6635945B2/ja active Active
- 2015-05-06 CN CN202011483141.5A patent/CN112741836A/zh active Pending
- 2015-05-06 EP EP24157482.1A patent/EP4389227A3/en not_active Withdrawn
- 2015-05-06 RS RS20240380A patent/RS65359B1/sr unknown
- 2015-05-06 ES ES21178882T patent/ES2976207T3/es active Active
- 2015-05-06 RS RS20220008A patent/RS62782B1/sr unknown
- 2015-05-06 KR KR1020227034399A patent/KR20220140647A/ko not_active Ceased
- 2015-05-06 SM SM20240199T patent/SMT202400199T1/it unknown
- 2015-05-06 LT LTEPPCT/US2015/029519T patent/LT3139925T/lt unknown
- 2015-05-06 DK DK21178882.3T patent/DK3936130T3/da active
- 2015-05-06 PT PT211788823T patent/PT3936130T/pt unknown
- 2015-05-06 PT PT157244385T patent/PT3139925T/pt unknown
- 2015-05-06 FI FIEP21178882.3T patent/FI3936130T3/fi active
- 2015-05-06 CA CA2947736A patent/CA2947736C/en active Active
- 2015-05-06 DK DK15724438.5T patent/DK3139925T3/da active
- 2015-05-06 MX MX2016014429A patent/MX387625B/es unknown
- 2015-05-06 RU RU2016147523A patent/RU2753740C2/ru active
- 2015-05-06 PL PL21178882.3T patent/PL3936130T3/pl unknown
- 2015-05-06 EP EP21178882.3A patent/EP3936130B1/en active Active
- 2015-05-06 AU AU2015256012A patent/AU2015256012B2/en active Active
- 2015-05-06 KR KR1020257005033A patent/KR20250029267A/ko active Pending
- 2015-05-06 LT LTEP21178882.3T patent/LT3936130T/lt unknown
- 2015-05-06 ES ES15724438T patent/ES2904526T3/es active Active
- 2015-05-06 WO PCT/US2015/029519 patent/WO2015171802A1/en not_active Ceased
- 2015-05-06 CN CN202011483135.XA patent/CN112741835A/zh active Pending
- 2015-05-06 SI SI201532006T patent/SI3936130T1/sl unknown
- 2015-05-06 IL IL248745A patent/IL248745B/en unknown
- 2015-05-06 HU HUE15724438A patent/HUE057839T2/hu unknown
- 2015-05-06 US US15/309,108 patent/US20170071932A1/en not_active Abandoned
- 2015-05-06 CN CN201580023821.XA patent/CN106456629A/zh active Pending
- 2015-05-06 PL PL15724438T patent/PL3139925T3/pl unknown
- 2015-05-06 SI SI201531799T patent/SI3139925T1/sl unknown
- 2015-05-06 KR KR1020247001490A patent/KR20240011255A/ko not_active Ceased
- 2015-05-06 SM SM20220193T patent/SMT202200193T1/it unknown
- 2015-05-06 KR KR1020207032879A patent/KR20200133003A/ko not_active Ceased
- 2015-05-06 HR HRP20240459TT patent/HRP20240459T1/hr unknown
- 2015-05-06 NZ NZ725826A patent/NZ725826A/en unknown
- 2015-05-06 KR KR1020167033765A patent/KR20160147044A/ko not_active Ceased
- 2015-05-06 HR HRP20220025TT patent/HRP20220025T1/hr unknown
- 2015-05-06 EP EP15724438.5A patent/EP3139925B1/en active Active
- 2015-05-06 HU HUE21178882A patent/HUE066361T2/hu unknown
-
2019
- 2019-10-02 JP JP2019181949A patent/JP2019218407A/ja not_active Withdrawn
- 2019-12-03 US US16/701,339 patent/US20200101063A1/en not_active Abandoned
-
2020
- 2020-09-15 US US17/021,362 patent/US20210196702A1/en not_active Abandoned
-
2021
- 2021-09-22 JP JP2021153918A patent/JP2021191799A/ja not_active Withdrawn
-
2022
- 2022-02-07 CY CY20221100104T patent/CY1125058T1/el unknown
-
2024
- 2024-07-29 JP JP2024122223A patent/JP2024153782A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220025T1 (hr) | Režim doziranja valbenazina za liječenje hiperkinetičkih poremećaja kretanja | |
| HRP20250250T1 (hr) | Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| HRP20211543T1 (hr) | Derivati kinazolina koji se koriste za liječenje hiv-a | |
| TN2018000121A1 (en) | Valbenazine salts and polymorphs thereof | |
| IL257481B (en) | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof | |
| WO2016210180A3 (en) | Vmat2 inhibitors for treating neurological diseases or disorders | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| JP2017514871A5 (cg-RX-API-DMAC7.html) | ||
| HRP20190537T1 (hr) | Farmaceutske kombinacije koje sadrže inhibitor b-raf, inhibitor egfr i po izboru inhibitor pi3k-alfa | |
| HRP20210529T1 (hr) | Inhibitori za mk2 i njihove uporabe | |
| EP4233846A3 (en) | Pharmaceutical formulations | |
| JP2012180381A5 (cg-RX-API-DMAC7.html) | ||
| JP2015038135A5 (cg-RX-API-DMAC7.html) | ||
| HUE052332T2 (hu) | Heteroaril-származék vagy gyógyászatilag elfogadható sója, eljárás annak elõállítására, és az ezeket hatóanyagént tartalmazó gyógyászati készítmény PI3 kinázokkal összefüggõ betegségek megelõzésére vagy kezelésére | |
| NZ729252A (en) | Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof | |
| BR112017028140A2 (pt) | formulações farmacêuticas | |
| EP3400964A4 (en) | TASTE-MASKED AND ORAL ADMINISTRATIVE PHARMACEUTICAL PREPARATION WITH VARENICLIN OR PHARMACEUTICAL SALT OF IT | |
| HRP20240309T1 (hr) | Kombinirani antibakterijski pripravak i kratkotrajni antibakterijski režim, koji uključuje linezolid, bedakvilin i pretomanid | |
| EP3162804A8 (en) | New benzodiazepine derivative and use thereof | |
| EP3784214C0 (en) | ORAL LIQUID PHARMACEUTICAL DOSAGE FORM | |
| MX385518B (es) | FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE. | |
| WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
| PH12016500666A1 (en) | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome | |
| PT3215143T (pt) | Combinação compreendendo espirulina e palmitoíletanolamida |